Diabetic Macular Edema Clinical Trial
Official title:
A Safety and Efficacy Study of VEGFA-targeting Gene Therapy to Treat Refractory Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).
Status | Recruiting |
Enrollment | 18 |
Est. completion date | September 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patients with nAMD at the age =50; Or patients with diabetic macular edema (DME) at the age =18; Or patients with macular edema following retinal vein occlusion (RVO-ME) at the age =18. 2. Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity =63 and letter score =19 Corresponding Snellen vision =20/63 and =20/400). 3. OCT confirms the presence of intraretinal fluid or subretinal fluid in the fovea. 4. Have received anti-VEGF therapy in the past and have responded to anti-VEGF therapy. 5. With refractory conditions: repeated anti-VEGF treatments are required due to the disease condition. When the treatment is interrupted, the disease condition recurs (OCT examination indicates increased subretinal/inner effusion in the macula) 6. For patients with both eyes suffered, enroll the one with more severe condition. 7. Routine blood test, liver and kidney function, coagulation index of patients is normal:AST/ALT < 2.5 × ULN; TB < 1.5 × ULN; PT < 1.5 × ULN; Hb > 10 g/dL (male) and > 9 g/dL (female); PLT > 100 × 10^3/µL; eGFR > 30 mL/min/1.73 m^2. Subjects voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up. Exclusion Criteria: 1. Choroidal neovascularization or macular edema induced by other diseases. 2. Any other factors that affect vision improvement in the study eye, such as fibrosis, atrophy, or RPE tear in the fovea of the macula. 3. The study eye already has severe proliferative retinopathy, such as retinal neovascularization, traction retinal detachment, etc. (only for DME and RVO-ME patients) . 4. Retinal detachment or advanced glaucoma in the study eye. 5. Implants in the study eye (except intraocular lenses). 6. Received internal eye surgery within 3 months prior to enrollment. 7. Vitrectomy surgery on the study eye. 8. Received intravitreal glucocorticoid or other clinical research drugs (except anti-VEGF therapy) within 6 months prior to enrollment. 9. Myocardial infarction, cerebrovascular accident or transient ischemic attack occurred within 6 months prior to enrollment. 10. Poorly controlled hypertension under maximum medication (systolic blood pressure>180 mmHg, diastolic blood pressure>100 mmHg). 11. Poor blood glucose control under medication (fasting blood glucose is greater than or equal to 10.0 umol/L). 12. Women who are willing to give birth; pregnant/breastfeeding women Have received gene therapy in the past. |
Country | Name | City | State |
---|---|---|---|
China | Eye & ENT Hospital of Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai BDgene Co., Ltd. | Eye & ENT Hospital of Fudan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment-related adverse events | Observe and record incidences of AE and SAE related to VEGFA-targeting gene therapy drug BD311 (IDLV expressing VEGFA antibody) administration. | At multiple timepoints after infusion up to 12 months. | |
Secondary | Changes in macular intraretinal fluid (IRF) | The presence of macular intraretinal fluid (IRF) will be determined by optical coherence tomography (OCT). | At multiple timepoints after infusion up to 12 months. | |
Secondary | Changes in subretinal fluid (SRF) | The presence of subretinal fluid (SRF) will be determined by optical coherence tomography (OCT). | At multiple timepoints after infusion up to 12 months. | |
Secondary | Change in central retinal thickness (CRT) | Central retinal thickness will be measured by Optical Coherence Tomography (OCT). | At multiple timepoints after infusion up to 12 months. | |
Secondary | Changes in the area of choroidal neovascularization | Using Fluorescein angiography (FFA) and indocyanine green angiography (ICGA) to assess the areas of choroidal neovascularization. Only for patients with nAMD. | At multiple timepoints after infusion up to 12 months. | |
Secondary | Changes in the area of fluorescein leakage | Using Fluorescein angiography (FFA) and indocyanine green angiography (ICGA) to assess the areas of fluorescein leakage. Only for patients with nAMD. | At multiple timepoints after infusion up to 12 months. | |
Secondary | The number of rescue treatments | Rescue treatments that require vitreous anti-VEGF injections due to illness. | At multiple timepoints after infusion up to 12 months. | |
Secondary | Evaluate the visual improvement | Subjects will be examined for best corrected visual acuity (BCVA). | At multiple timepoints after infusion up to 12 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04603937 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A |